<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977454</url>
  </required_header>
  <id_info>
    <org_study_id>2000025198</org_study_id>
    <nct_id>NCT03977454</nct_id>
  </id_info>
  <brief_title>Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty</brief_title>
  <official_title>Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty: a Single Center Randomized Controlled Trail (RCT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB)&#xD;
      with ropivacaine and glucocorticoids provide more effective analgesia than periarticular&#xD;
      injection (PAI) with the same mixture in total hip arthroplasty (THA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To support our hypothesis that preoperative quadratus lumborum block (QLB)/lateral femoral&#xD;
      cutaneous nerve block (LFCNB) provides more effective analgesia than periarticular injection&#xD;
      (PAI) in total hip arthroplasty (THA), we will look at the following outcomes:&#xD;
&#xD;
      Primary outcome: Daily opioid consumption&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        1. Pain intensity and physical functioning while in the hospital: using pain inventory&#xD;
           modified from Brief Pain Inventory 23, see attached;&#xD;
&#xD;
        2. Boston mobility scores (from physical therapy note);&#xD;
&#xD;
        3. Clinical Quality Improvement (CQI) data: White blood cell (WBC), serum glucose and&#xD;
           complications;&#xD;
&#xD;
        4. Length of hospital stays;&#xD;
&#xD;
        5. Surgical outcome by Patient Reported Outcomes Measurement Information System (PROMIS)&#xD;
           scores at 2-weeks postop in surgeon office to be collected by researchers.&#xD;
&#xD;
      Since both QLB/LFCNB nerve block and PAI techniques are both routinely used as standard of&#xD;
      care anesthesia for THA, the study intervention will be the randomization to assign patients&#xD;
      to one of these treatment options and assess their response from post-op patient&#xD;
      questionnaires and data collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Actual">June 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily opioid consumption</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>Daily opioid consumption will be monitored during the patient's post surgical hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity while in hospital</measure>
    <time_frame>2 days</time_frame>
    <description>Pain intensity will be assessed using a pain inventory modified from Brief Pain Inventory 23.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>The patient's post surgical length of stay in the hospital will be compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>2 weeks post operation</time_frame>
    <description>The Harris Hip Score (HHS) assesses post operative conditions following hip surgery. The HHS uses a 100 point score wherethe scores are interpreted as follows: &lt; 70 = poor, 70-79 = fair, 80-89 = good and 90-100 = excellent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Hip Arthropathy</condition>
  <arm_group>
    <arm_group_label>Group 1 patients will receive nerve block per standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service.&#xD;
QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and&#xD;
LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 will NOT receive any nerve blocks.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve Block</intervention_name>
    <description>Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.&#xD;
QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA&#xD;
LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA</description>
    <arm_group_label>Group 1 patients will receive nerve block per standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Periarticular Injection (PAI)</intervention_name>
    <description>Intraoperatively, the surgeon will perform PAI per standard of care with the medications:&#xD;
1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA</description>
    <arm_group_label>Group 2 will NOT receive any nerve blocks.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>60 ml 0.2% ropivacaine</description>
    <arm_group_label>Group 1 patients will receive nerve block per standard of care</arm_group_label>
    <arm_group_label>Group 2 will NOT receive any nerve blocks.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dex</intervention_name>
    <description>10 mg DEX/ 80 mg MPA</description>
    <arm_group_label>Group 2 will NOT receive any nerve blocks.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective unilateral primary THA&#xD;
&#xD;
          -  All surgical approaches&#xD;
&#xD;
          -  American Society of Anesthesiologist (ASA) status I, II and III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal;&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Those with cognitive dysfunction, psychiatric disorder, or non-English speaking&#xD;
             patients that cannot consent or communicate clear understanding of the protocol with&#xD;
             research team;&#xD;
&#xD;
          -  Coagulopathy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinlei Li, MD PhD FASA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital St Raphael</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

